Intradigm Licenses Key Next Generation RNAi Intellectual Property from U of M Medical School
News Apr 10, 2008
Intradigm Corporation has announced that it has licensed key intellectual property (IP) covering certain efficacy-enhancing structural elements of small interfering RNA (siRNA) from the University of Massachusetts Medical School.
The licensed IP includes parameters for the structural modifications for next generation siRNAs including the "Zamore Design Rules" that significantly improve the potency and efficacy of RNAi therapeutics. This licensed technology allows Intradigm to incorporate novel siRNA sequences into the company's proprietary RNAi delivery systems to create potent and effective siRNA therapeutics.
The company announced this licensing agreement as part of its presentation at the Bio-Europe Spring 2008 conference in Madrid, Spain.
The technology licensed from the University of Massachusetts Medical School provides Intradigm with a strong IP position around structural features for a next generation of siRNA molecules.
Additionally, Intradigm also possesses a strong IP position surrounding biodegradable polycationic polymers for the delivery of RNAi therapeutics which the company further strengthened through its recent licensing of complementary technology from the Massachusetts Institute of Technology (MIT).
This licensed RNAi IP estate, combined with Intradigm's delivery technology and proprietary siRNA sequences, positions the company as a leader in the RNAi therapeutic space, the company says.
"By licensing this important IP from the University of Massachusetts Medical School, which we believe to be the clear center of excellence for breakthrough siRNA academic research, Intradigm has taken another critical step toward its goal of establishing itself as a leader in the development and commercialization of novel RNAi therapeutics," said Mohammad Azab, M.D., president and chief executive officer of Intradigm.
"We have established an impressive IP portfolio that spans the areas of siRNA structure and sequence, as well as RNAi delivery, providing us a distinct competitive advantage enjoyed by very few other companies," Azab added.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019